Advertisement
UK markets close in 7 hours 23 minutes
  • FTSE 100

    8,123.43
    +44.57 (+0.55%)
     
  • FTSE 250

    19,751.79
    +149.81 (+0.76%)
     
  • AIM

    755.63
    +2.51 (+0.33%)
     
  • GBP/EUR

    1.1659
    +0.0003 (+0.02%)
     
  • GBP/USD

    1.2515
    +0.0004 (+0.03%)
     
  • Bitcoin GBP

    51,356.17
    +180.59 (+0.35%)
     
  • CMC Crypto 200

    1,388.57
    -7.96 (-0.57%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    84.00
    +0.43 (+0.51%)
     
  • GOLD FUTURES

    2,357.00
    +14.50 (+0.62%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,662.55
    +378.01 (+2.19%)
     
  • DAX

    18,029.34
    +112.06 (+0.63%)
     
  • CAC 40

    8,042.05
    +25.40 (+0.32%)
     

Analysts Are Bullish on Viking Therapeutics Stock

Analysts Are Bullish on Viking Therapeutics Stock

Viking Therapeutics’ (VKTX) stock price rose ~101% on May 31 following the successful trial results of Madrigal Pharmaceuticals’ (MDGL) NASH drug. Madrigal Pharmaceuticals’ drug has a similar mechanism of action as Viking Pharmaceuticals’ NASH drug. In this part, we’ll discuss Wall Street analysts’ recommendations for Viking Therapeutics stock in the next 12 months.